Advertisement

Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea

  • Hye-Jae Lee
  • Euna HanEmail author
  • Hyero Kim
Original Research Article

Abstract

Background

South Korea is unique in that it leads global markets in R&D as well as production of biosimilar products and was the first market into which some biosimilar products were introduced. We analyzed the time trend of market penetration and simulated saved spending by biosimilars in South Korea.

Methods

We pulled Korean National Health Insurance claims data from January 2012–December 2018 for second-generation biologics, including infliximab, rituximab, and trastuzumab, and examined the time trends of expenditure, utilization in defined daily dose, and price. We also assessed market penetration by biosimilars and simulated expenditure savings gained due to their introduction. We comparatively examined time trends and spending savings during the same period for selected small-molecule generic drugs to understand any specifics limited to biosimilars for time trends of market share and quantity-standardized prices.

Results

The market share for infliximab biosimilar plateaued at over 30%, which is smaller than the market penetration of esomeprazole (over 60%), a small-molecule comparator. Despite a shorter observation period, rituximab and trastuzumab biosimilars also showed larger utilization rates (12.89% and 13.93%, respectively) than infliximab (9.05%) in their second year after market entry. Infliximab was associated with approximately US $82–114 million expenditure savings over 6 years after its biosimilar entry to the market. Rituximab and trastuzumab biosimilars each also resulted in reduction in total spending by approximately US $9–14 million, in less than 2 years.

Conclusion

Biosimilars captured the market rapidly, despite a heterogeneous uptake rate by product in South Korea. However, expansion of biosimilar use in the market and consequent expenditure savings need to be supported by pre-emptive policy measures to encourage price competition and boost utilization.

Notes

Author contributions

EH and HJL conceived the study. HJL performed data cleaning and analyses and EH verified the analytical methods. HK performed the literature review. EH and HJL drafted the manuscript. All authors discussed the results and commented on the manuscript.

Compliance with Ethical Standards

Conflict of interest

Research support from the Korea National Research Foundation [Grant number 2019R1A2C1003259] is gratefully acknowledged. The content is solely the responsibility of the authors and does not necessarily represent the official view of the Korea National Research Foundation. The Korea National Research Foundation had no involvement in preparation and submission of this manuscript. The authors declare that they have no competing interests.

References

  1. 1.
    Organisation for Economic Co-operation and Development. Health at a Glance 2017. In: OECD Indicaors. OECD Publishing, Paris. 2017. https://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2017_health_glance-2017-en. Accessed 28 Jun 2019.
  2. 2.
    Belloni A, Morgan D, Paris V. Pharmaceutical expenditure and policies: past trends and future challenges. OECD Health Working Paper No. 87. Paris: Organisation for Economic Co-operation and Development; 2016.Google Scholar
  3. 3.
    Organisation for Economic Co-operation and Development. Pharmaceutical innovation and access to medicines. In: OECD Health Policy Studies. OECD Publishing, Paris. 2018. https://www.oecd-ilibrary.org/content/publication/9789264307391-en. Accessed 28 Jun 2019.
  4. 4.
    Araujo FC, Goncalves J, Fonseca JE. Pharmacoeconomics of biosimilars: what is there to gain from them? Curr Rheumatol Rep. 2016;18(8):50.  https://doi.org/10.1007/s11926-016-0601-0.PubMedCrossRefGoogle Scholar
  5. 5.
    Haustein R, de Millas C, Hoer A, Haussler B. Saving money in the European healthcare systems with biosimilars. Generics Biosimilars Initiative J. 2012;1(3–4):120–6.CrossRefGoogle Scholar
  6. 6.
    Jha A, Upton A, Dunlop WC, Akehurst R. The Budget Impact of Biosimilar Infliximab (Remsima(R)) for the treatment of autoimmune diseases in five European countries. Adv Ther. 2015;32(8):742–56.  https://doi.org/10.1007/s12325-015-0233-1.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Manova M, Savova A, Vasileva M, Terezova S, Kamusheva M, Grekova D, et al. Comparative price analysis of biological products for treatment of rheumatoid arthritis. Front Pharmacol. 2018;9:1070.  https://doi.org/10.3389/fphar.2018.01070.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Quart. 2018;7(4):3.Google Scholar
  9. 9.
    Fraeyman J, Van Hal G, De Loof H, Remmen R, De Meyer GR, Beutels P. Potential impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium. Acta Clin Belg. 2012;67(3):160–71.  https://doi.org/10.2143/ACB.67.3.2062650.PubMedCrossRefGoogle Scholar
  10. 10.
    Luo J, Seeger JD, Donneyong M, Gagne JJ, Avorn J, Kesselheim AS. Effect of generic competition on atorvastatin prescribing and patients’ out-of-pocket spending. JAMA Intern Med. 2016;176(9):1317–23.  https://doi.org/10.1001/jamainternmed.2016.3384.PubMedCrossRefGoogle Scholar
  11. 11.
    Nador A, Pratt JL, Rix E. The Canadian Competition Bureau releases benefitting from generic drug competition in Canada: the way forward. Health Law Can. 2009;29(3):54–5.PubMedGoogle Scholar
  12. 12.
    Puig-Junoy J. Impact of European pharmaceutical price regulation on generic price competition: a review. Pharmacoeconomics. 2010;28(8):649–63.  https://doi.org/10.2165/11535360-000000000-00000.PubMedCrossRefGoogle Scholar
  13. 13.
    Sheingold S, Nguyen NX. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare’s Part D benefit. Medicare Medicaid Res Rev. 2014.  https://doi.org/10.5600/mmrr.004.01.a01.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Kim SC, Choi N-K, Lee J, Kwon K-E, Eddings W, Sung Y-K, et al. Utilization of the first biosimilar infliximab since its approval in South Korea. Arthritis Rheumatol. 2016;68(5):1076–9.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Jung Sowon, Lee Tae-Jin, Cho Byung-Hee. Market competition after patent exprity of original medicines. Korean J Health Econ Pol. 2008;14(2):1–25.Google Scholar
  16. 16.
    Bae G, Park C, Lee H, Han E, Kim D-S, Jang S. Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea. BMC Health Serv Res. 2014;14(1):100.  https://doi.org/10.1186/1472-6963-14-100.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Son K-B, Bae S. Patterns of statin utilisation for new users and market dynamics in South Korea: a 13-year retrospective cohort study. BMJ Open. 2019;9(3):e026603.  https://doi.org/10.1136/bmjopen-2018-026603.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Kwon H-Y, Yang B-M. Do generics really create savings on drug expenditures? Korean J Health Econ Pol. 2011;17(4):1–20.Google Scholar
  19. 19.
    Cesarec A, Likic R. Budget impact analysis of biosimilar trastuzumab for the treatment of breast cancer in Croatia. Appl Health Econ Health Pol. 2017;15(2):277–86.  https://doi.org/10.1007/s40258-016-0285-7.CrossRefGoogle Scholar
  20. 20.
    Gulacsi L, Brodszky V, Baji P, Rencz F, Pentek M. The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries. Adv Ther. 2017;34(5):1128–44.  https://doi.org/10.1007/s12325-017-0522-y.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Kanters TA, Stevanovic J, Huys I, Vulto AG, Simoens S. Adoption of biosimilar infliximab for rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel diseases in the EU5: a budget impact analysis using a Delphi panel. Front Pharmacol. 2017;8:322.  https://doi.org/10.3389/fphar.2017.00322.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Araújo F. Biosimilar DMARDs: what does the future hold? Drugs (New York, NY). 2016;76(6):629–37.  https://doi.org/10.1007/s40265-016-0556-5.CrossRefGoogle Scholar
  23. 23.
    Brodszky V, Baji P, Balogh O, Péntek M. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ. 2014;15(1):65–71.  https://doi.org/10.1007/s10198-014-0595-3.PubMedCentralCrossRefGoogle Scholar
  24. 24.
    Whitehouse J. The cost saving potential of utilizing biosimilar medicines in biologic naive severe rheumatoid arthritis patients. Value Health. 2013.  https://doi.org/10.1016/j.jval.2013.08.1547.CrossRefGoogle Scholar
  25. 25.
    Sarpatwari A, Barenie R, Curfman G, Darrow J, Kesselheim AS. The US biosimilar market: stunted growth and possible reforms. Clin Pharmacol Ther. 2019;105(1):92–100.PubMedCrossRefGoogle Scholar
  26. 26.
    Kim J, Ha D, Song I, Park H, Lee S-W, Lee E-K, et al. Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database. Int J Rheumatic Dis. 2018;21(6):1227–36.CrossRefGoogle Scholar
  27. 27.
    Grabowski H, Guha R, Salgado M. Biosimilar competition: lessons from Europe. Berlin: Nature Publishing Group; 2014.Google Scholar
  28. 28.
    Schellekens H, Smolen JS, Dicato M, Rifkin RM. Safety and efficacy of biosimilars in oncology. Lancet Oncol. 2016;17(11):e502–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Candelaria M, Gonzalez D, Gómez FJF, Paravisini A, García ADC, Pérez L, et al. Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach. Cancer Chemother Pharmacol. 2018;81(3):515–27.PubMedCrossRefGoogle Scholar
  30. 30.
    Verrill M, Declerck P, Loibl S, Lee J, Cortes J. The rise of oncology biosimilars: from process to promise. Future Oncol. 2019.  https://doi.org/10.2217/fon-2019-0145.PubMedCrossRefGoogle Scholar
  31. 31.
    Weaver AL, Lautzenheiser RL, Schiff MH, Gibofsky A, Perruquet JL, Luetkemeyer J, et al. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Curr Med Res opin. 2006;22(1):185–98.PubMedCrossRefGoogle Scholar
  32. 32.
    Kwon H-Y, Kim H, Godman B, Reich MR. The impact of South Korea’s new drug-pricing policy on market competition among off-patent drugs. Exp Rev Pharmacoecon Outcomes Res. 2015;15(6):1007–14.  https://doi.org/10.1586/14737167.2015.1083425.CrossRefGoogle Scholar
  33. 33.
    World Health Organization Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2019. Oslo, Norway; 2018.Google Scholar
  34. 34.
    Rovira J, Espin J, Garcia L, de Labry AO. The impact of biosimilars’ entry in the EU market. Andalusian School Public Health. 2011.Google Scholar
  35. 35.
    Remuzat C, Dorey J, Cristeau O, Ionescu D, Radiere G, Toumi M. Key drivers for market penetration of biosimilars in Europe. J Market Access Health Pol. 2017;5(1):1272308.CrossRefGoogle Scholar
  36. 36.
    Morton FMS, Stern AD, Stern S. The impact of the entry of biosimilars: evidence from Europe. Rev Ind Organ. 2016;53:173–210.  https://doi.org/10.1007/s11151-018-9630-3.CrossRefGoogle Scholar
  37. 37.
    de Lemos ML, Kyritsis V. Clinical efficacy of generic imatinib. J Oncol Pharm Pract. 2015;21(1):76–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Canada CMLSo. Generic tyrosine kinase inhibitors (TKIs) arrive in Canada. Chronic Myelogenous Leukemia Society of Canada. 2014. http://cmlsociety.org/generic-tyrosine-kinase-inhibitors-tkis-arrive-in-canada/. Accessed 29 Apr 2019.
  39. 39.
    International G-GS. Generic Gleevec. GIS-GIST Support International. 2013. http://gistsupport.medshelf.org/Generic_Gleevec. Accessed 29 Apr 2019.
  40. 40.
    Goubran HA. Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report. J Med Case Rep. 2009;3(1):7112.  https://doi.org/10.1186/1752-1947-3-7112.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Cole AL, Dusetzina SB. Generic price competition for specialty drugs: too little, too late? Health Aff (Millwood). 2018;37(5):738–42.  https://doi.org/10.1377/hlthaff.2017.1684.PubMedCrossRefGoogle Scholar
  42. 42.
    van de Vooren K, Curto A, Garattini L. Biosimilar versus generic drugs: same but different? Appl Health Econ Health Pol. 2015;13:125–7.  https://doi.org/10.1007/s40258-015-0154-9.CrossRefGoogle Scholar
  43. 43.
    Sullivan E, Piercy J, Waller J, Black CM, Kachroo S. Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn’s disease across Germany. PLoS One. 2017;12(4):e0175826.  https://doi.org/10.1371/journal.pone.0175826.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Waller J, Sullivan E, Piercy J, Black CM, Kachroo S. Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany. Patient Preference Adherence. 2017;11:519.PubMedCrossRefGoogle Scholar
  45. 45.
    Berndt ER, Aitken ML. Brand loyalty, generic entry and price competition in pharmaceuticals in the quarter century after the 1984 Waxman–Hatch legislation. Int J Econ Business. 2011;18(2):177–201.CrossRefGoogle Scholar
  46. 46.
    Kurki P, van Aerts L, Wolff-Holz E, Giezen T, Skibeli V, Weise M. Interchangeability of biosimilars: a European perspective. BioDrugs. 2017;31(2):83–91.PubMedCrossRefGoogle Scholar
  47. 47.
    O’Callaghan J, Barry SP, Bermingham M, Morris JM, Griffin BT. Regulation of biosimilar medicines and current perspectives on interchangeability and policy. Eur J Clin Pharmacol. 2019;75(1):1–11.PubMedCrossRefGoogle Scholar
  48. 48.
    Cohen H, Beydoun D, Chien D, Lessor T, McCabe D, Muenzberg M, et al. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther. 2016;33(12):2160–72.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Menditto E, Orlando V, Coretti S, Putignano D, Fiorentino D, Ruggeri M. Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs. ClinicoEcon Outcomes Res. 2015;7:575–81.  https://doi.org/10.2147/CEOR.S88531.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469–78.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Crommelin D, Bermejo T, Bissig M, Damiaans J, Kramer I, Rambourg P. Pharmaceutical evaluation of biosimilars: important differences from generic low-molecular-weight pharmaceuticals. Eur J Hosp Pharm Sci. 2005;11(1):11–7.Google Scholar
  52. 52.
    Garattini L, Curto A, van de Vooren K. Western European markets for biosimilar and generic drugs: worth differentiating. Eur J Health Econ. 2015;16:683–7.  https://doi.org/10.1007/s10198-015-0684-y.PubMedCrossRefGoogle Scholar
  53. 53.
    Health Insurance Review and Assessment Service. Statistics for Pharmaceutical Reimbursement Claims. In: Statistics for Pharmaceutical Reimbursement Claims by Utilization Type. Health Insurance Review and Assessment Service, Wonju. 2018. http://kosis.kr/common/meta_onedepth.jsp?vwcd=MT_OTITLE&listid=354_354004. Accessed 2 Oct 2019.
  54. 54.
    Aladul MI, Fitzpatrick RW, Chapman SR. Patients’ understanding and attitudes towards infliximab and etanercept biosimilars: result of a UK web-based survey. BioDrugs. 2017;31(5):439–46.  https://doi.org/10.1007/s40259-017-0238-1.PubMedCrossRefGoogle Scholar
  55. 55.
    Yazdany J, Dudley RA, Lin GA, Chen R, Tseng CW. Out-of-pocket costs for infliximab and its biosimilar for rheumatoid arthritis under medicare part D. JAMA. 2018;320(9):931–3.  https://doi.org/10.1001/jama.2018.7316.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Mestre-Ferrandiz J, Towse A, Berdud M. Biosimilars: how can payers get long-term savings? Pharmacoeconomics. 2016;34(6):609–16.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Mrazek M. Comparative approaches to pharmaceutical price regulation in the European Union. Croatian Med J. 2002;43(4):453–61.Google Scholar
  58. 58.
    Brems Y, Seville J, Baeyens J. The expanding world market of generic pharmaceuticals. J Generic Med. 2011;8(4):227–39.CrossRefGoogle Scholar
  59. 59.
    Woori Bank. Average exchange rate by period. Seoul. 2018. https://spot.wooribank.com/pot/Dream?withyou=FXXRT0016. Accessed 10 Dec 2019.

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.National Health Insurance Research Institute, National Health Insurance ServiceWonjuSouth Korea
  2. 2.College of PharmacyWoosuk UniversityWanju-gunSouth Korea
  3. 3.College of Pharmacy, Yonsei Institute for Pharmaceutical ResearchYonsei UniversityIncheonSouth Korea

Personalised recommendations